Citations (35)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (7)
Antonio Tapia-Galisteo, Íñigo Sánchez Rodríguez, Oscar Aguilar-Sopeña, Seandean Lykke Harwood, Javier Narbona, Mariola Ferreras Gutierrez, Rocío Navarro, Laura Martín-García, Cesáreo Corbacho, Marta Compte, Javier Lacadena, Francisco J. Blanco, Patrick Chames, Pedro Roda-Navarro, Luis Álvarez-Vallina & Laura Sanz. (2022) Trispecific T-cell engagers for dual tumor-targeting of colorectal cancer. OncoImmunology 11:1.
Read now
Read now
Leonie Enderle, Karim H. Shalaby, Maryna Gorelik, Alexander Weiss, Levi L. Blazer, Marcin Paduch, Lia Cardarelli, Anthony Kossiakoff, Jarrett J. Adams & Sachdev S. Sidhu. (2021) A T cell redirection platform for co-targeting dual antigens on solid tumors. mAbs 13:1.
Read now
Read now
Bo Wang, Chunning Yang, Xiaofang Jin, Qun Du, Herren Wu, William Dall’Acqua & Yariv Mazor. (2020) Regulation of antibody-mediated complement-dependent cytotoxicity by modulating the intrinsic affinity and binding valency of IgG for target antigen. mAbs 12:1.
Read now
Read now
Xiling Jiang, Xi Chen, Thomas J. Carpenter, Jun Wang, Rebecca Zhou, Hugh M. Davis, Donald L. Heald & Weirong Wang. (2018) Development of a Target cell-Biologics-Effector cell (TBE) complex-based cell killing model to characterize target cell depletion by T cell redirecting bispecific agents. mAbs 10:6, pages 876-889.
Read now
Read now
Bram G. Sengers, Sean McGinty, Fatma Z. Nouri, Maryam Argungu, Emma Hawkins, Aymen Hadji, Andrew Weber, Adam Taylor & Armin Sepp. (2016) Modeling bispecific monoclonal antibody interaction with two cell membrane targets indicates the importance of surface diffusion. mAbs 8:5, pages 905-915.
Read now
Read now
Juergen M. Schanzer, Katharina Wartha, Ekkehard Moessner, Ralf J. Hosse, Samuel Moser, Rebecca Croasdale, Halina Trochanowska, Cuiying Shao, Peng Wang, Lei Shi, Tina Weinzierl, Natascha Rieder, Marina Bacac, Carola H. Ries, Hubert Kettenberger, Tilman Schlothauer, Thomas Friess, Pablo Umana & Christian Klein. (2016) XGFR*, a novel affinity-matured bispecific antibody targeting IGF-1R and EGFR with combined signaling inhibition and enhanced immune activation for the treatment of pancreatic cancer. mAbs 8:4, pages 811-827.
Read now
Read now
Jin Niu, Weirong Wang & Daniele Ouellet. Mechanism-based pharmacokinetic and pharmacodynamic modeling for bispecific antibodies: challenges and opportunities. Expert Review of Clinical Pharmacology 0:0, pages 1-14.
Read now
Read now
Articles from other publishers (28)
Brian J. Thomas, Caitlyn Guldenpfennig, Yue Guan, Calvin Winkler, Margaret Beecher, Michaela Beedy, Ashley F. Berendzen, Lixin Ma, Mark A. Daniels, Donald H. Burke & David Porciani. (2023) Targeting lung cancer with clinically relevant EGFR mutations using anti-EGFR RNA aptamer. Molecular Therapy - Nucleic Acids 34, pages 102046.
Crossref
Crossref
Jason J. Luke, Manish R. Patel, George R. Blumenschein, Erika Hamilton, Bartosz Chmielowski, Susanna V. Ulahannan, Roisin M. Connolly, Cesar A. Santa-Maria, Jie Wang, Shakeela W. Bahadur, Andrew Weickhardt, Adam S. Asch, Girish Mallesara, Philip Clingan, Monika Dlugosz-Danecka, Monika Tomaszewska-Kiecana, Halyna Pylypenko, Nada Hamad, Hedy L. Kindler, Bradley J. Sumrow, Patrick Kaminker, Francine Z. Chen, Xiaoyu Zhang, Kalpana Shah, Douglas H. Smith, Anushka De Costa, Jonathan Li, Hua Li, Jichao Sun & Paul A. Moore. (2023) The PD-1- and LAG-3-targeting bispecific molecule tebotelimab in solid tumors and hematologic cancers: a phase 1 trial. Nature Medicine 29:11, pages 2814-2824.
Crossref
Crossref
Jingwen Liu, Yan Xiang, Tingwen Fang, Lulin Zeng, Ao Sun, Yixiang Lin & Kaihua Lu. (2023) Advances in the diagnosis and treatment of advanced non-small cell lung cancer with EGFR exon 20 insertion mutation. Clinical Lung Cancer.
Crossref
Crossref
Danielle Brazel & Misako Nagasaka. (2023) The development of amivantamab for the treatment of non-small cell lung cancer. Respiratory Research 24:1.
Crossref
Crossref
Liang-Chun Wu, Seiichi Tada, Takashi Isoshima, Takeshi Serizawa & Yoshihiro Ito. (2023) Photo-reactive polymers for the immobilisation of epidermal growth factors. Journal of Materials Chemistry B 11:24, pages 5514-5522.
Crossref
Crossref
Yanze Sun, Xinmiao Yu, Xiao Wang, Kai Yuan, Gefei Wang, Lingrong Hu, Guoyu Zhang, Wenli Pei, Liping Wang, Chengliang Sun & Peng Yang. (2023) Bispecific antibodies in cancer therapy: Target selection and regulatory requirements. Acta Pharmaceutica Sinica B.
Crossref
Crossref
Emilia Rabia, Véronique Garambois, Christine Dhommée, Christel Larbouret, Laurie Lajoie, Yoan Buscail, Gabriel Jimenez-Dominguez, Sylvie Choblet-Thery, Emmanuelle Liaudet-Coopman, Martine Cerutti, Marta Jarlier, Patrice Ravel, Laurent Gros, Nelly Pirot, Gilles Thibault, Eugene A. Zhukovsky, Pierre-Emmanuel Gérard, André Pèlegrin, Jacques Colinge & Thierry Chardès. (2023) Design and selection of optimal ErbB-targeting bispecific antibodies in pancreatic cancer. Frontiers in Immunology 14.
Crossref
Crossref
Byoung Chul Cho, Allison Simi, Joshua Sabari, Smruthi Vijayaraghavan, Sheri Moores & Alexander Spira. (2023) Amivantamab, an Epidermal Growth Factor Receptor (EGFR) and Mesenchymal-epithelial Transition Factor (MET) Bispecific Antibody, Designed to Enable Multiple Mechanisms of Action and Broad Clinical Applications. Clinical Lung Cancer 24:2, pages 89-97.
Crossref
Crossref
Tian Li, Changhai Lei & Shi Hu. 2023. Novel Sensitizing Agents for Therapeutic Anti-EGFR Antibodies. Novel Sensitizing Agents for Therapeutic Anti-EGFR Antibodies
105
111
.
Simone C. Oostindie, Greg A. Lazar, Janine Schuurman & Paul W. H. I. Parren. (2022) Avidity in antibody effector functions and biotherapeutic drug design. Nature Reviews Drug Discovery 21:10, pages 715-735.
Crossref
Crossref
Rebecca S. Goydel & Christoph Rader. (2021) Antibody-based cancer therapy. Oncogene 40:21, pages 3655-3664.
Crossref
Crossref
Ames C. Register, Somayeh S. Tarighat & Ho Young Lee. (2021) Bioassay Development for Bispecific Antibodies—Challenges and Opportunities. International Journal of Molecular Sciences 22:10, pages 5350.
Crossref
Crossref
Simon J. Dovedi, Matthew J. Elder, Chunning Yang, Suzanne I. Sitnikova, Lorraine Irving, Anna Hansen, James Hair, Des C. Jones, Sumati Hasani, Bo Wang, Seock-Ah Im, Ben Tran, Deepa S. Subramaniam, Shelby D. Gainer, Kapil Vashisht, Arthur Lewis, Xiaofang Jin, Stacy Kentner, Kathy Mulgrew, Yaya Wang, Michael G. Overstreet, James Dodgson, Yanli Wu, Asis Palazon, Michelle Morrow, Godfrey J. Rainey, Gareth J. Browne, Frances Neal, Thomas V. Murray, Aleksandra D. Toloczko, William Dall'Acqua, Ikbel Achour, Daniel J. Freeman, Robert W. Wilkinson & Yariv Mazor. (2021) Design and Efficacy of a Monovalent Bispecific PD-1/CTLA4 Antibody That Enhances CTLA4 Blockade on PD-1+ Activated T Cells. Cancer Discovery 11:5, pages 1100-1117.
Crossref
Crossref
Rui-Fang Dong, Miao-Lin Zhu, Ming-Ming Liu, Yi-Ting Xu, Liu-Liu Yuan, Jing Bian, Yuan-Zheng Xia & Ling-Yi Kong. (2021) EGFR mutation mediates resistance to EGFR tyrosine kinase inhibitors in NSCLC: From molecular mechanisms to clinical research. Pharmacological Research 167, pages 105583.
Crossref
Crossref
Smruthi Vijayaraghavan, Lorraine Lipfert, Kristen Chevalier, Barbara S. Bushey, Benjamin Henley, Ryan Lenhart, Jocelyn Sendecki, Marilda Beqiri, Hillary J. Millar, Kathryn Packman, Matthew V. Lorenzi, Sylvie Laquerre & Sheri L. Moores. (2020) Amivantamab (JNJ-61186372), an Fc Enhanced EGFR/cMet Bispecific Antibody, Induces Receptor Downmodulation and Antitumor Activity by Monocyte/Macrophage Trogocytosis. Molecular Cancer Therapeutics 19:10, pages 2044-2056.
Crossref
Crossref
Sung In Lim. (2020) Fine-tuning bispecific therapeutics. Pharmacology & Therapeutics 212, pages 107582.
Crossref
Crossref
Mark L. Chiu, Dennis R. Goulet, Alexey Teplyakov & Gary L. Gilliland. (2019) Antibody Structure and Function: The Basis for Engineering Therapeutics. Antibodies 8:4, pages 55.
Crossref
Crossref
Aran F. Labrijn, Maarten L. Janmaat, Janice M. Reichert & Paul W. H. I. Parren. (2019) Bispecific antibodies: a mechanistic review of the pipeline. Nature Reviews Drug Discovery 18:8, pages 585-608.
Crossref
Crossref
Dionysos Slaga, Diego Ellerman, T. Noelle Lombana, Rajesh Vij, Ji Li, Maria HristopoulosRobyn Clark, Jennifer Johnston, Amy SheltonElaine MaiKapil GadkarAmy A. Lo, James T. Koerber, Klara TotpalRodney PrellGenee LeeChristoph Spiess & Teemu T. Junttila. (2018) Avidity-based binding to HER2 results in selective killing of HER2-overexpressing cells by anti-HER2/CD3. Science Translational Medicine 10:463.
Crossref
Crossref
Paul J. Carter & Greg A. Lazar. (2017) Next generation antibody drugs: pursuit of the 'high-hanging fruit'. Nature Reviews Drug Discovery 17:3, pages 197-223.
Crossref
Crossref
Nam-Kyung Lee, Yafeng Zhang, Yang Su, Scott Bidlingmaier, Daniel W. Sherbenou, Kevin D. Ha & Bin Liu. (2018) Cell-type specific potent Wnt signaling blockade by bispecific antibody. Scientific Reports 8:1.
Crossref
Crossref
Azhagiya Singam Ettayapuram Ramaprasad, Shahid Uddin, Jose Casas-Finet & Donald J. Jacobs. (2017) Decomposing Dynamical Couplings in Mutated scFv Antibody Fragments into Stabilizing and Destabilizing Effects. Journal of the American Chemical Society 139:48, pages 17508-17517.
Crossref
Crossref
Thorsten Gantke, Michael Weichel, Carmen Herbrecht, Uwe Reusch, Kristina Ellwanger, Ivica Fucek, Markus Eser, Thomas Müller, Remko Griep, Vera Molkenthin, Eugene A Zhukovsky & Martin Treder. (2017) Trispecific antibodies for CD16A-directed NK cell engagement and dual-targeting of tumor cells. Protein Engineering, Design and Selection 30:9, pages 673-684.
Crossref
Crossref
Yariv Mazor, Kris F. Sachsenmeier, Chunning Yang, Anna Hansen, Jessica Filderman, Kathy Mulgrew, Herren Wu & William F. Dall’Acqua. (2017) Enhanced tumor-targeting selectivity by modulating bispecific antibody binding affinity and format valence. Scientific Reports 7:1.
Crossref
Crossref
Giulia M. Stella, Alessandra Gentile, Alice Balderacchi, Federica Meloni, Melissa Milan & Silvia Benvenuti. (2016) Ockham’s razor for the MET-driven invasive growth linking idiopathic pulmonary fibrosis and cancer. Journal of Translational Medicine 14:1.
Crossref
Crossref
Carolin Sellmann, Achim Doerner, Christine Knuehl, Nicolas Rasche, Vanita Sood, Simon Krah, Laura Rhiel, Annika Messemer, John Wesolowski, Mark Schuette, Stefan Becker, Lars Toleikis, Harald Kolmar & Bjoern Hock. (2016) Balancing Selectivity and Efficacy of Bispecific Epidermal Growth Factor Receptor (EGFR) × c-MET Antibodies and Antibody-Drug Conjugates. Journal of Biological Chemistry 291:48, pages 25106-25119.
Crossref
Crossref
Raffaella Castoldi, J?rgen Schanzer, Christian Panke, Ute Jucknischke, Natalie J. Neubert, Rebecca Croasdale, Werner Scheuer, Johannes Auer, Christian Klein, Gerhard Niederfellner, Sebastian Kobold & Claudio Sustmann. (2016) TetraMabs: simultaneous targeting of four oncogenic receptor tyrosine kinases for tumor growth inhibition in heterogeneous tumor cell populations. Protein Engineering Design and Selection 29:10, pages 467-475.
Crossref
Crossref
Sheri L. Moores, Mark L. Chiu, Barbara S. Bushey, Kristen Chevalier, Leopoldo Luistro, Keri Dorn, Randall J. Brezski, Peter Haytko, Thomas Kelly, Sheng-Jiun Wu, Pauline L. Martin, Joost Neijssen, Paul W.H.I. Parren, Janine Schuurman, Ricardo M. Attar, Sylvie Laquerre, Matthew V. Lorenzi & G. Mark Anderson. (2016) A Novel Bispecific Antibody Targeting EGFR and cMet Is Effective against EGFR Inhibitor–Resistant Lung Tumors. Cancer Research 76:13, pages 3942-3953.
Crossref
Crossref